Developer docs
API playgroundTry for free, no card

Search company profiles

Stem Pharm

Full company profile

uuid00037dc

Namestring
Stem Pharm
Legal namestring
Stem Pharm, Inc.
Websiteurl
stempharm.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Stem Pharm is a Madison, Wisconsin-based private biotechnology company founded in 2015 that provides human iPSC-derived neural organoid platforms and chemically-defined synthetic substrates for neuroimmune drug discovery. Its core technology centers on 3D human neural organoids composed of neurons, astrocytes, vascular cells, and microglia — the brain's resident immune cells — produced in a scalable 96-well plate format that enables high-throughput phenotypic screening not feasible with traditional 2D cultures or rodent models. The organoid platform is paired with proprietary PEG-based hydrogel products (SureCoat pre-coated plates and Ready-To-Dispense Hydrogels SP-105 and SP-111) that serve as chemically-defined, animal-component-free alternatives to Matrigel, targeting applications in Alzheimer's disease, Parkinson's disease, temporal lobe epilepsy, glioblastoma, and developmental neurotoxicity.

The company monetizes through three streams: (1) fee-for-service contracts covering bespoke organoid generation, disease modeling, assay development, phenotypic screening, and custom biomaterials for pharma, biotech, and academic clients; (2) direct product sales of SureCoat plates and SP-105/SP-111 hydrogels via contact-based pricing, accessible also through scientific marketplaces (Science Exchange, Scientist.com, LifeScience Marketplace); and (3) non-dilutive NIH SBIR/STTR grant funding ($3.2M+ disclosed across NIEHS, NINDS, NIA, NCI). Go-to-market is consultative and science-led, anchored by named enterprise collaborations with InMed Pharmaceuticals (Alzheimer's preclinical validation for INM-901) and Verge Genomics (Parkinson's target validation), supported by conference presence (SfN, ISSCR, SLAS, BIO, MPS World Summit), accelerator memberships (Illumina Accelerator, Merck Digital Sciences Studio, StartUp Health Alzheimer's Moonshot), and an active peer-reviewed publication record.

Stem Pharm is led by CEO Steven Visuri (12+ FDA product approvals), COO Connie Lebakken (co-founder), CSO Bill Murphy (UW-Madison professor, 170+ publications, 50+ patent applications), and Sr. VP of Business Development Ryan Gordon (previously StemoniX), with an advisor roster spanning microglia biology, neurosurgery, and venture capital. The company is qualified as a New Business Venture through the Wisconsin Economic Development Corporation, holds 1-10 employees, and is publicly soliciting investment on its website, indicating active fundraising posture rather than established commercial scale.

Short descriptiontext

Stem Pharm is a Madison, Wisconsin-based biotechnology company that provides human iPSC-derived neural organoids containing microglia and synthetic PEG-based hydrogel substrates for neuroimmune drug discovery. It serves pharmaceutical, biotech, and academic research customers in Alzheimer's, Parkinson's, epilepsy, glioblastoma, and neurotoxicology through fee-for-service contracts and product sales.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMadison, United States
HQ citystring
Madison
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neural organoid models, preclinical drug discovery, synthetic hydrogel substrates, neuroinflammation research, iPSC-derived cell models
Industry3 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Medical Laboratories8071
  • Laboratory Analytical Instruments3826
Product category
Preclinical Drug Discovery Services
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Fee-for-Service Drug Discovery Contracts
TypeProfessional Services
Description

Stem Pharm provides fee-for-service drug discovery and partnering arrangements to pharmaceutical companies, biotech firms, and academic researchers. Services include neurological disease modeling, assay development, phenotypic drug screening, and neurotoxicity assessments. Revenue is project-based, likely with multi-phase engagements.

stempharm.com
2Synthetic Substrate Products
TypeHardware Sales
Description

Sale of proprietary synthetic substrate products including SureCoat pre-coated cell culture plates and Ready-To-Dispense Hydrogels (SP-105, SP-111). Products are sold directly to customers for cell culture and assay applications. Contact-based pricing model.

stempharm.com
3NIH SBIR/STTR Grant Funding
TypeLicensing Royalties
Description

Stem Pharm has received multiple SBIR and STTR grants from NIH institutes (NIEHS, NINDS, NIA, NCI) totaling approximately $3.2M+ in disclosed funding. These non-dilutive grants support R&D programs and represent a revenue stream for research activities.

stempharm.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details3 tiers
1SureCoat Pre-Coated Plates — standard catalog product with contact-based pricing
ModelOtherBilling cadencePay-as-you-go
Notes

Ready-to-use, shelf-stable plates. Pricing available upon inquiry via info@stempharm.com.

stempharm.com
2Ready-To-Dispense Hydrogels (SP-105, SP-111) — custom formulations
ModelUnit PricingBilling cadencePay-as-you-go
Notes

SP-105 for vascular tubulogenesis assays; SP-111 for spheroid/organoid encapsulation. Custom hydrogel development also available. Pricing requires direct contact.

stempharm.com
3Fee-for-Service / Pilot Projects
ModelOtherBilling cadenceMulti-year contract
Notes

Pilot projects are offered as an evaluation mechanism. Services include bespoke organoid generation, assay services, and custom biomaterials. Pricing determined per project through inquiry.

stempharm.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1SureCoat
Description

Synthetic substrate technology and pre-coated cell culture plates trademark of Stem Pharm, Inc.

stempharm.com
Core offering1 text field

Stem Pharm develops and sells human iPSC-derived 3D neural organoids featuring incorporated microglia (alongside neurons, astrocytes, and vascular cells) for neuroimmune drug discovery. The platform is paired with proprietary chemically-defined PEG-based hydrogel substrates (SureCoat pre-coated plates, SP-105, SP-111 ready-to-dispense hydrogels) that replace animal-derived Matrigel. Offerings are delivered as catalog products and via fee-for-service drug discovery contracts covering disease modeling, assay development, phenotypic screening, and neurotoxicity assessment.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • INM-901 showed dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8 in human brain organoid models of Alzheimer's disease (InMed collaboration)
+3 more records
Product overview1 text field

Stem Pharm is a drug discovery platform company offering a portfolio of human neural organoid products and services for neurological disease research. The core offering is their Human Neural Organoids platform, which provides physiologically relevant 3D in vitro models featuring microglia for neuroimmune drug discovery. This core platform is complemented by synthetic substrate products including SureCoat Pre-Coated Cell Culture Plates and ready-to-dispense hydrogels (SP-105 and SP-111). The company also provides fee-for-service offerings including neurological disease models, assay services, and custom biomaterials development. Stem Pharm operates through both direct partnerships and marketplace platforms including Science Exchange, Scientist.com, and LifeScience Marketplace.

Product and service7 records
1Human Neural Organoids
CategoryPreclinical Drug Discovery Products
Description

3D human neural organoids derived from iPSCs and composed of neurons, astrocytes, vascular cells, and microglia. Designed for neuroimmune drug discovery, neuroinflammation modeling, and modeling of human neurodegenerative features that are not observable in rodent models.

2SureCoat Pre-Coated Cell Culture Plates
CategorySynthetic Substrates
Description

Pre-coated cell culture plates using Stem Pharm's chemically-defined synthetic substrate to optimize adhesion, accelerate cell maturation, enhance phenotypes, and improve assay performance across iPSC-derived neural cells, iPSCs, MSCs, and endothelial cells.

3SP-105 Hydrogel
CategorySynthetic Substrates
Description

Ready-to-dispense, chemically-defined PEG-based hydrogel optimized for in vitro cellular assays and vascular tubulogenesis with HUVEC and iPSC-derived endothelial cells; non-toxic, optically clear, automation-compatible, supplied frozen.

4SP-111 Hydrogel
CategorySynthetic Substrates
Description

Ready-to-dispense chemically-defined hydrogel designed for encapsulation and expansion of spheroids and organoids, supplied at 2X concentration to allow dilution and customization of the biomechanical environment; non-toxic, optically clear, automation-compatible.

5Neurological Disease Modeling Services
CategoryDrug Discovery Services
Description

Fee-for-service neurological disease modeling including bespoke organoid generation, neuroinflammation modeling, microglia target studies, neurogenesis and neurodevelopment assays, neurodevelopmental toxicology, and glioblastoma models targeting Alzheimer's, Parkinson's, epilepsy, and developmental neurotoxicology.

6Drug Discovery Assay Services
CategoryDrug Discovery Services
Description

Fee-for-service drug discovery assay services including co-culture models, vascular tubulogenesis assays, immunoassays (cytokines, chemokines), high-content imaging, transcriptional analysis (bulk and single-cell RNA-seq), bioinformatics support, and phenotypic screens for pharma, biotech, and academic partners.

7Custom Biomaterials Development
CategoryCustom Biomaterials Services
Description

Custom biomaterials development including customized hydrogels, customized synthetic coatings, design-of-experiments (DOE)-based biomaterial optimization, and biomaterial design support and testing services for partner cell-therapy, regenerative-medicine, and drug-discovery programs.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

Stem Pharm provides its human brain organoid neuroinflammation models to InMed Pharmaceuticals for preclinical validation of INM-901, an Alzheimer's disease drug candidate. Studies demonstrated dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8 in 3D human brain organoid models, supporting InMed's planned IND filing and Phase 1 trial initiation in 2027.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-05-22
Description

Selected among first companies to join StartUp Health's Alzheimer's Moonshot, a collaborative innovation community supported by Gates Ventures and Alzheimer's Drug Discovery Foundation (ADDF), focused on advancing Alzheimer's disease drug discovery through innovation and partnership.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-10
Description

Collaboration to develop a disease model to validate novel targets identified by Verge Genomics for Parkinson's disease. Stem Pharm contributes its 3D neuro-immune organoid platform; Verge Genomics contributes AI-driven target identification from patient tissue data.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-10
Description

NCI STTR grant-supported collaboration with Dr. Mahua Dey (Assistant Professor of Neurological Surgery) and Dr. Christian Capitini (Associate Professor of Pediatrics) at UW-Madison to develop neural organoid models for studying the immunological microenvironment of glioblastoma.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-12-20
Description

Stem Pharm joined the first biopharmaceutical cohort of Merck Digital Sciences Studio, a 10-month accelerator program involving Merck, Microsoft for Startups, and New Jersey Innovation Institute. Cohort companies can pilot technologies with Merck discovery and clinical scientists. Direct investments from Merck Global Health Innovation Fund, Northpond Ventures, and McKesson Ventures.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2021-10-01
Description

Stem Pharm joined the NA3RsC Microphysiological Systems (MPS) Initiative working to refine, reduce, and replace animals in research. Listed under CNS, tumor, and vascular solutions as an MPS technology provider, enhancing industry visibility and regulatory acceptance.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2019-10-21
Description

Selected for Illumina Accelerator's 10th funding cycle (Cycle 10), gaining access to sequencing systems, reagents, and lab space in San Francisco Bay Area over six months. Stem Pharm planned to use next-generation sequencing resources to validate the physiologic relevance of its cell and tissue models.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stem Pharm

Preclinical Drug Discovery Servicesstempharm.com

Stem Pharm is a Madison, Wisconsin-based biotechnology company that provides human iPSC-derived neural organoids containing microglia and synthetic PEG-based hydrogel substrates for neuroimmune drug discovery. It serves pharmaceutical, biotech, and academic research customers in Alzheimer's, Parkinson's, epilepsy, glioblastoma, and neurotoxicology through fee-for-service contracts and product sales.

What Stem Pharm does

Stem Pharm is a Madison, Wisconsin-based private biotechnology company founded in 2015 that provides human iPSC-derived neural organoid platforms and chemically-defined synthetic substrates for neuroimmune drug discovery. Its core technology centers on 3D human neural organoids composed of neurons, astrocytes, vascular cells, and microglia — the brain's resident immune cells — produced in a scalable 96-well plate format that enables high-throughput phenotypic screening not feasible with traditional 2D cultures or rodent models. The organoid platform is paired with proprietary PEG-based hydrogel products (SureCoat pre-coated plates and Ready-To-Dispense Hydrogels SP-105 and SP-111) that serve as chemically-defined, animal-component-free alternatives to Matrigel, targeting applications in Alzheimer's disease, Parkinson's disease, temporal lobe epilepsy, glioblastoma, and developmental neurotoxicity.

The company monetizes through three streams: (1) fee-for-service contracts covering bespoke organoid generation, disease modeling, assay development, phenotypic screening, and custom biomaterials for pharma, biotech, and academic clients; (2) direct product sales of SureCoat plates and SP-105/SP-111 hydrogels via contact-based pricing, accessible also through scientific marketplaces (Science Exchange, Scientist.com, LifeScience Marketplace); and (3) non-dilutive NIH SBIR/STTR grant funding ($3.2M+ disclosed across NIEHS, NINDS, NIA, NCI). Go-to-market is consultative and science-led, anchored by named enterprise collaborations with InMed Pharmaceuticals (Alzheimer's preclinical validation for INM-901) and Verge Genomics (Parkinson's target validation), supported by conference presence (SfN, ISSCR, SLAS, BIO, MPS World Summit), accelerator memberships (Illumina Accelerator, Merck Digital Sciences Studio, StartUp Health Alzheimer's Moonshot), and an active peer-reviewed publication record.

Stem Pharm is led by CEO Steven Visuri (12+ FDA product approvals), COO Connie Lebakken (co-founder), CSO Bill Murphy (UW-Madison professor, 170+ publications, 50+ patent applications), and Sr. VP of Business Development Ryan Gordon (previously StemoniX), with an advisor roster spanning microglia biology, neurosurgery, and venture capital. The company is qualified as a New Business Venture through the Wisconsin Economic Development Corporation, holds 1-10 employees, and is publicly soliciting investment on its website, indicating active fundraising posture rather than established commercial scale.

Stem Pharm firmographics

Firmographics
Name
Stem Pharm
Legal name
Stem Pharm, Inc.
Website
https://stempharm.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Stem Pharm is a Madison, Wisconsin-based biotechnology company that provides human iPSC-derived neural organoids containing microglia and synthetic PEG-based hydrogel substrates for neuroimmune drug discovery. It serves pharmaceutical, biotech, and academic research customers in Alzheimer's, Parkinson's, epilepsy, glioblastoma, and neurotoxicology through fee-for-service contracts and product sales.
Ownership category
akta.pro rank

Stem Pharm industry classification

Industry
Product category
Preclinical Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Neural organoid models
  • Preclinical drug discovery
  • Synthetic hydrogel substrates
  • Neuroinflammation research
  • IPSC-derived cell models

Where Stem Pharm is headquartered

Location

Headquarters

HQ city
Madison
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Stem Pharm business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Fee-for-Service Drug Discovery Contracts: Stem Pharm provides fee-for-service drug discovery and partnering arrangements to pharmaceutical companies, biotech firms, and academic researchers. Services include neurological disease modeling, assay development, phenotypic drug screening, and neurotoxicity assessments. Revenue is project-based, likely with multi-phase engagements.
  2. Synthetic Substrate Products: Sale of proprietary synthetic substrate products including SureCoat pre-coated cell culture plates and Ready-To-Dispense Hydrogels (SP-105, SP-111). Products are sold directly to customers for cell culture and assay applications. Contact-based pricing model.
  3. NIH SBIR/STTR Grant Funding: Stem Pharm has received multiple SBIR and STTR grants from NIH institutes (NIEHS, NINDS, NIA, NCI) totaling approximately $3.2M+ in disclosed funding. These non-dilutive grants support R&D programs and represent a revenue stream for research activities.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goSureCoat Pre-Coated Plates — standard catalog product with contact-based pricing
Unit PricingPay-as-you-goReady-To-Dispense Hydrogels (SP-105, SP-111) — custom formulations
OtherMulti-year contractFee-for-Service / Pilot Projects

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Stem Pharm product offering

Product offering

Core offering

Stem Pharm develops and sells human iPSC-derived 3D neural organoids featuring incorporated microglia (alongside neurons, astrocytes, and vascular cells) for neuroimmune drug discovery. The platform is paired with proprietary chemically-defined PEG-based hydrogel substrates (SureCoat pre-coated plates, SP-105, SP-111 ready-to-dispense hydrogels) that replace animal-derived Matrigel. Offerings are delivered as catalog products and via fee-for-service drug discovery contracts covering disease modeling, assay development, phenotypic screening, and neurotoxicity assessment.

Product overview

Stem Pharm is a drug discovery platform company offering a portfolio of human neural organoid products and services for neurological disease research. The core offering is their Human Neural Organoids platform, which provides physiologically relevant 3D in vitro models featuring microglia for neuroimmune drug discovery. This core platform is complemented by synthetic substrate products including SureCoat Pre-Coated Cell Culture Plates and ready-to-dispense hydrogels (SP-105 and SP-111). The company also provides fee-for-service offerings including neurological disease models, assay services, and custom biomaterials development. Stem Pharm operates through both direct partnerships and marketplace platforms including Science Exchange, Scientist.com, and LifeScience Marketplace.

Differentiator

Problem solved

Functional benefit

Brands

  • SureCoat: Synthetic substrate technology and pre-coated cell culture plates trademark of Stem Pharm, Inc.

Products and services

  • Human Neural Organoids 3D human neural organoids derived from iPSCs and composed of neurons, astrocytes, vascular cells, and microglia. Designed for neuroimmune drug discovery, neuroinflammation modeling, and modeling of human neurodegenerative features that are not observable in rodent models.
  • SureCoat Pre-Coated Cell Culture Plates Pre-coated cell culture plates using Stem Pharm's chemically-defined synthetic substrate to optimize adhesion, accelerate cell maturation, enhance phenotypes, and improve assay performance across iPSC-derived neural cells, iPSCs, MSCs, and endothelial cells.
  • SP-105 Hydrogel Ready-to-dispense, chemically-defined PEG-based hydrogel optimized for in vitro cellular assays and vascular tubulogenesis with HUVEC and iPSC-derived endothelial cells; non-toxic, optically clear, automation-compatible, supplied frozen.
  • SP-111 Hydrogel Ready-to-dispense chemically-defined hydrogel designed for encapsulation and expansion of spheroids and organoids, supplied at 2X concentration to allow dilution and customization of the biomechanical environment; non-toxic, optically clear, automation-compatible.
  • Neurological Disease Modeling Services Fee-for-service neurological disease modeling including bespoke organoid generation, neuroinflammation modeling, microglia target studies, neurogenesis and neurodevelopment assays, neurodevelopmental toxicology, and glioblastoma models targeting Alzheimer's, Parkinson's, epilepsy, and developmental neurotoxicology.
  • Drug Discovery Assay Services Fee-for-service drug discovery assay services including co-culture models, vascular tubulogenesis assays, immunoassays (cytokines, chemokines), high-content imaging, transcriptional analysis (bulk and single-cell RNA-seq), bioinformatics support, and phenotypic screens for pharma, biotech, and academic partners.
  • Custom Biomaterials Development Custom biomaterials development including customized hydrogels, customized synthetic coatings, design-of-experiments (DOE)-based biomaterial optimization, and biomaterial design support and testing services for partner cell-therapy, regenerative-medicine, and drug-discovery programs.

Quantifiable outcome

  • INM-901 showed dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8 in human brain organoid models of Alzheimer's disease (InMed collaboration)
  • +3 more outcomes

Companies that use Stem Pharm

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Stem Pharm technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

Feature5 records

Stem Pharm partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • InMed PharmaceuticalscoreStrategic or Co-development Partner · 23 March 2026Stem Pharm provides its human brain organoid neuroinflammation models to InMed Pharmaceuticals for preclinical validation of INM-901, an Alzheimer's disease drug candidate. Studies demonstrated dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8 in 3D human brain organoid models, supporting InMed's planned IND filing and Phase 1 trial initiation in 2027.
  • StartUp Health (Alzheimer's Moonshot)minorGTM or Marketing Partner · 22 May 2024Selected among first companies to join StartUp Health's Alzheimer's Moonshot, a collaborative innovation community supported by Gates Ventures and Alzheimer's Drug Discovery Foundation (ADDF), focused on advancing Alzheimer's disease drug discovery through innovation and partnership.
  • Verge GenomicscoreStrategic or Co-development Partner · 10 October 2023Collaboration to develop a disease model to validate novel targets identified by Verge Genomics for Parkinson's disease. Stem Pharm contributes its 3D neuro-immune organoid platform; Verge Genomics contributes AI-driven target identification from patient tissue data.
  • University of Wisconsin-Madison (Dr. Mahua Dey, Dr. Christian Capitini)coreStrategic or Co-development Partner · 10 August 2023NCI STTR grant-supported collaboration with Dr. Mahua Dey (Assistant Professor of Neurological Surgery) and Dr. Christian Capitini (Associate Professor of Pediatrics) at UW-Madison to develop neural organoid models for studying the immunological microenvironment of glioblastoma.
  • Merck Digital Sciences StudiominorStrategic or Co-development Partner · 20 December 2022Stem Pharm joined the first biopharmaceutical cohort of Merck Digital Sciences Studio, a 10-month accelerator program involving Merck, Microsoft for Startups, and New Jersey Innovation Institute. Cohort companies can pilot technologies with Merck discovery and clinical scientists. Direct investments from Merck Global Health Innovation Fund, Northpond Ventures, and McKesson Ventures.
  • North American 3Rs Collaborative (NA3RsC)minorGTM or Marketing Partner · 1 October 2021Stem Pharm joined the NA3RsC Microphysiological Systems (MPS) Initiative working to refine, reduce, and replace animals in research. Listed under CNS, tumor, and vascular solutions as an MPS technology provider, enhancing industry visibility and regulatory acceptance.
  • Illumina AcceleratorminorGTM or Marketing Partner · 21 October 2019Selected for Illumina Accelerator's 10th funding cycle (Cycle 10), gaining access to sequencing systems, reagents, and lab space in San Francisco Bay Area over six months. Stem Pharm planned to use next-generation sequencing resources to validate the physiologic relevance of its cell and tissue models.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Stem Pharm competitors and assessment

Company assessment

Market position

Strengths5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Stem Pharm social profiles

Digital presence

Stem Pharm compliance and trust

Trust signal

Compliance1 record

Stem Pharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stem Pharm leadership team

Management profile

Number of profiles

Profiles4 records

Stem Pharm funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stem Pharm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stem Pharm

What does Stem Pharm do?

Stem Pharm develops and sells human iPSC-derived 3D neural organoids featuring incorporated microglia (alongside neurons, astrocytes, and vascular cells) for neuroimmune drug discovery. The platform is paired with proprietary chemically-defined PEG-based hydrogel substrates (SureCoat pre-coated plates, SP-105, SP-111 ready-to-dispense hydrogels) that replace animal-derived Matrigel. Offerings are delivered as catalog products and via fee-for-service drug discovery contracts covering disease modeling, assay development, phenotypic screening, and neurotoxicity assessment.

Is Stem Pharm a public or private company?

Stem Pharm is a private company. It is classified as venture growth investor backed and is currently operating.

When was Stem Pharm founded?

Stem Pharm was founded in 2015. It employs 1 to 10 people.

Where is Stem Pharm based?

Stem Pharm is headquartered in Madison, United States, in the North America region.

How does Stem Pharm make money?

Three revenue lines are on record. Fee-for-Service Drug Discovery Contracts are the primary driver. The others are synthetic Substrate Products and NIH SBIR/STTR Grant Funding.

Does Stem Pharm have an API?

No public API is recorded for Stem Pharm.

What industry is Stem Pharm in?

Stem Pharm's product category is Preclinical Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 541714 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MadisonstartupsStem Pharm Receives $2.5M NIH Grant - Startup and Tech News - Madison StartupsStem Pharm received a $2.5 million Phase II SBIR grant from the NIH's NIA. The funds will support its Alzheimer's drug discovery project using a human organoid model of neuroinflammation. CEO Dr. Steven Visuri said the award enables scaling the platform to identify new therapeutics.Stock TitanInMed Alzheimer’s drug cuts inflammation in brain organoidsInMed Pharmaceuticals announced positive preclinical data showing its INM-901 drug candidate significantly reduces neuroinflammation in 3D human brain organoid models of Alzheimer's disease, demonstrating dose-dependent reduction of pro-inflammatory markers including IL-6 and IL-8. The studies, conducted in collaboration with Stem Pharm using their proprietary human neuro-immune organoid platform, showed consistent anti-inflammatory effects that translate from prior animal model results to human-relevant systems. The company plans to conduct a pre-IND meeting with the FDA in Q3 2026 and targets submission of an Investigational New Drug application and initiation of a Phase 1 clinical trial in 2027.FOX6 News MilwaukeeFeds push animal testing alternatives; Wisconsin laboratory leads the wayThe FDA and NIH announced plans to incentivize new approach methodologies, such as 3D organoids, to reduce or eliminate animal testing in drug research over the next three to five years. Madison-based biotech startup Stem Pharm is actively developing these human-based models for Alzheimer's treatment, securing nearly $6 million in federal funding to advance its research.MadisonstartupsSix Local Companies Receive SBIR Advance Funds - Startup and Tech News - Madison StartupsSix Madison-area businesses received SBIR Advance grants, announced by the Center for Technology Commercialization and the Wisconsin Economic Development Corporation. The grants, up to $800,000, match federal SBIR or STTR projects, with recipients including Atrility Medical, Stem Pharm, and GoDX Inc.ParkinsonsnewstodayCompanies will use 3D brain model of Parkinson's to find therapies...Stem Pharm and Verge Genomics have partnered to develop a 3D brain model of Parkinson’s disease using Stem Pharm's neuroimmune organoids and Verge's ConVERGE discovery platform. This collaboration aims to leverage advanced computational tools and human genomics to identify and validate new therapeutic candidates for the disease.News-MedicalUW-Madison researchers jump major hurdle on path toward wider use of stem cellsUW-Madison researchers developed an automated screening test and synthetic substrates to replace Matrigel for growing stem cells. The materials, granted two U.S. patents, are produced entirely from chemicals, eliminating risks from mouse-derived proteins. A UW-Madison spinoff, Stem Pharm, has licensed the patents and is selling the system to pharmaceutical companies.